written on 27.02.2014

Specialty focus enables UCB to repel austerity


By focusing on specialty drugs for severe neurological and immunology disorders UCB CEO Roch Doliveux believes his company is positioned well to cope with payer pressures in the developed world while making major headway in key emerging markets. Indeed,…